Geftinat 250 mg | Gefitinib for Lung Cancer Treatment

Introduction of Geftinat 250 mg

Geftinat 250 mg is an anti-cancer medication used in the treatment of non-small cell lung cancer (NSCLC). It contains gefitinib, which belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). This targeted therapy works by blocking abnormal protein signals (EGFR) responsible for the growth and spread of cancer cells, thereby slowing or stopping tumor progression.

Geftinat is commonly prescribed to patients with EGFR mutation-positive NSCLC, particularly when other treatments have failed or are not suitable. It is typically taken orally and is often part of a long-term cancer management plan.

✅ Key Uses of Geftinat 250 mg

• Treatment of non-small cell lung cancer (NSCLC)
  
  

• Specifically used in patients with EGFR gene mutations
  
  

• Often prescribed as first-line therapy or when chemotherapy is not effective
  
  

✅ Common Side Effects

• Diarrhea
  
  

• Skin rash or dryness
  
  

• Nausea or vomiting
  
  

• Loss of appetite
  
  

• Weakness or fatigue
  
  

✅ Precautions and Warnings

• Not recommended during pregnancy or breastfeeding
  
  

• Inform your doctor if you have lung disease, liver disorders, or eye problems
  
  

• Regular blood tests and liver function monitoring may be required during treatment
  
  

• Avoid grapefruit and certain herbal supplements, as they may interact with the drug
  
  

• Not intended for use in children
  
  

✅ Storage Instructions

• Store at room temperature (15–30°C) in a dry place
  
  

• Keep away from direct sunlight and moisture
  
  

• Keep the medicine out of reach of children and pets